Zhitong Financial APP learned that Sino Biopharmaceutical (01177) fell more than 6%. As of press time, it fell 5.82% to HK $4.21, with a turnover of HK $51.851 million.

On the news side, Zhongsheng Pharmaceutical announced that during the six-month period ended June 30, 2022, due to the lower financial performance of an associate company than in the same period last year, the profit attributable to the group belonging to the parent company decreased by as much as 78% to about 1.871 billion yuan compared with the same period last year. The profit attributable to the joint venture decreased during the period, but the performance of the group's main business was in line with expectations and the performance grew steadily.

The analysis believes that the associate refers to Xingxing Zhongwei, a research and development company of New Crown Disease Miao Ke Laifu. It is reported that Sino Biopharmaceutical holds 15.03% of the shares of Sinovel. According to Sino Biopharmaceutical's semi-annual report disclosed on August 31, 2021, the profit attributable to the owner of the parent company is about 8.48 billion yuan, of which the joint venture company and the joint venture company contribute 7.585 billion yuan.